Three-phase 18F-fluorocholine PET/CT in the evaluation ... - CiteSeerX
Recommend Documents
Motivations for combined PET/CT ... Dual Energy. CT technique options in PET/
CT ... MR/PET. Commercial PET/CT Design. Gemini GXL. Discovery ST 16, 64.
(GTV, i.e. the macroscopic disease) (4, ... tives with those related to treatment ... schemes have been already shown ... Specific radiation therapy (RT) strategies can further address the tumor motion issue ..... compensation for respiratory move-.
evaluation approaches for assessing innovation and proposes an alternative ..... black youth in Chicago, sponsored by the Reverend Jesse Jackson; and the non- ..... numbers of publications, presentations, scientific awards, or peer or 'expert'.
Professional Consulting Firms (PCF) from the ... (IT) have the potential to affect business strategies, .... directed to computer systems, and communication.
Africa.1 Though expensive, vocational education and training in general ..... In Table 2, we look at training received during the previous year with the present.
For the latest information about departments of internal medicine, please visit APM's website at .... cilitate acceptance of the tools and methods used in.
Three-phase 18F-fluorocholine PET/CT in the evaluation ... - CiteSeerX
Jul 1, 2008 - Analysis Group; 1,2,3University Hospital of Geneva; 4Institute of Radiology Jean Violette, Geneva; .... All patients received a standard ac-.
Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence
Schattauer GmbH
3-Phasen-PET/CT mit 18 F-Fluorcholin zur Evaluation des Prostatakrebsrezidivs
Ch. Steiner1; H. Vees2; H. Zaidi1; M. Wissmeyer1; O. Berrebi1; M. P. Kossovsky3; H. G. Khan4; R. Miralbell2,5; O. Ratib1; F. Buchegger1,6 1 Service of Nuclear Medicine; 2 Service of Radiation Oncology; 3Hospital Care System Research and Analysis Group; 1,2,3University Hospital of Geneva; 4Institute of Radiology Jean Violette, Geneva; 6 Service of Nuclear Medicine, University Hospital of Lausanne; Switzerland; 5 Instituto Oncológico Teknon, Barcelona, Spain Keywords
Schlüsselwörter
18F-fluorocholine,
18F-Fluorcholin,
3-phase PET/CT, prostate cancer recurrence, rising PSA
PSA-Anstieg
Summary
Zusammenfassung
Aim: Contribution of 3-phase 18F-fluorocholine PET/CT in suspected prostate cancer recurrence at early rise of PSA. Patients, methods: Retrospective analysis was performed in 47 patients after initial treatment with radiotherapy (n = 30) or surgery (n = 17). Following CT, 10 minutes list-mode PET acquisition was done over the prostate bed after injection of 300 MBq of 18F-fluorocholine. Three timeframes of 3 minutes each were reconstructed for analysis. All patients underwent subsequent whole body PET/CT. Delayed pelvic PET/CT was obtained in 36 patients. PET/CT was interpreted visually by two observers and SUVmax determined for suspicious lesions. Biopsies were obtained from 13 patients. Results: Biopsies confirmed the presence of cancer in 11 of 13 patients with positive PET for a total of 15 local recurrences in which average SUVmax increased during 14 minutes post injection and marginally decreased in delayed scanning. Conversely inguinal lymph nodes with mild to moderate metabolic activity on PET showed a clearly different pattern with decreasing SUVmax on dynamic images. Three-phase PET/CT contributed to the diagnostic assessment of 10 of 47 patients with biological evidence of recurrence of cancer. It notably allowed the discrimination of confounding blood pool or urinary activity from suspicious hyperactivities. PET/CT was positive in all patients with PSA ≥ 2 ng/ml (n = 34) and in 4/13 patients presenting PSA values
